Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Split Dosing Semaglutide Twice Weekly: What the Label Says
articleSplit dosing semaglutide twice weekly takes the same total weekly dose and divides it into two injections about 3 to 4 days apart. Every semaglutide product is FDA-approved for once-weekly dosing only, so this is off-label. Here is the pharmacokinetic reasoning, the pen-mechanics problem, and what has never been tested.
Microdosing GLP-1 Reddit: What the Community Actually Reports
articleA community synthesis of what Reddit threads actually report about GLP-1 microdosing: fewer side effects, the "just 10 lbs" cohort, off-label inflammation use, and where anecdote meets pharmacokinetics. Anecdotes, not medical advice.
GLP-1 Microdosing Guide: How to Run a Sub-Standard Protocol
articleA practical how-to guide for running a GLP-1 microdosing protocol across semaglutide, tirzepatide, and retatrutide. Covers approach selection, compound-specific steps, titration decisions, and calculator modeling.
What Is Microdosing GLP-1? Definition, Benefits, and Risks Explained
articleWhat microdosing GLP-1 actually means, how it differs from standard titration, what clinical evidence exists, and the risks of using sub-standard doses of semaglutide, tirzepatide, or retatrutide.